Tyra Biosciences, Inc. is a pharmaceutical company in the United States specializing in precision medicines targeting opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. With an ESG score of 27.4, the company is at a medium risk level. Tyra Biosciences utilizes its in-house precision medicine platform, SNÅP, for rapid and precise drug design to predict genetic alterations causing resistance to existing therapies. Its lead product, TYRA 300, is an FGFR3 selective inhibitor focusing on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).